Publications by authors named "A Ravikumar Arunachalam"
Background: Cytomegalovirus (CMV) is associated with detrimental outcomes after lung transplantation (LTX); primary prophylaxis (PPX) with valganciclovir (VGC) is guideline-recommended. VGC is associated with myelosuppression, spurring interest in letermovir (LTV).
Methods: Adults undergoing LTX between January 1, 2021, and July 30, 2022 at our institution who were converted from VGC to LTV for PPX were evaluated.
Article Synopsis
- - In 2018, durvalumab, an immune checkpoint inhibitor, was introduced as a treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy; however, many still experienced cancer progression.
- - This study analyzed data from 426 patients who underwent concurrent chemoradiotherapy (cCRT) between 2017 and 2019, focusing on their survival and progression outcomes through a follow-up ending in 2022.
- - Results showed that patients who received cCRT plus durvalumab had a median overall survival of 50.2 months compared to 11.6 months for those who only had cCRT, indicating a significant benefit from adding durvalumab
Article Synopsis
- Right heart remodeling is commonly observed in patients suffering from severe COVID-19-related acute respiratory distress syndrome (ARDS), but there is limited information on the recovery of the right heart following lung transplantation for these patients.
- A study at Northwestern University analyzed data from 36 patients who underwent lung transplantation for COVID-19-related ARDS between June 2020 and June 2022, finding that none of the patients died within 90 days, and the 1-year survival rate was 88.8%.
- Postoperative evaluations revealed significant improvements in right ventricle (RV) size and function, as well as reduced pulmonary artery pressure, indicating that right heart recovery can occur relatively quickly after lung transplantation in this specific patient population.
Background: Treatment for first-line (1L) metastatic non-small cell cancer (mNSCLC) changed with the introduction of immunotherapy. We describe treatment utilization and clinical outcomes in a real-world mNSCLC cohort in a 2.7-million-member state-mandated health provider.
View Article and Find Full Text PDFIntroduction: We map the patient journey from symptom onset to intervention and describe primary treatment in a retrospective population-based cohort study of patients in a large healthcare-provider.
Methods: Newly diagnosed adult patients diagnosed with stages I-III non-small cell lung cancer (NSCLC) between 2016 and 2019 were identified from the Israel National Cancer Registry and chart review was performed to extract de-identified data. The following timelines were constructed: from symptom onset to imaging, imaging to biopsy, and biopsy to primary treatment initiation.